3 Dec 2018

Pharmac urged to fund 'breakthrough' drug for cystic fibrosis

From Nine To Noon, 9:07 am on 3 December 2018
No caption

Photo: supplied

People living with the debilitating respiratory condition cystic fibrosis want Pharmac to fund a breakthrough new drug treatment for a group of 30 patients.

NZ is the only country in the OECD which doesn't publicly fund the drug Kalydeco, which effectively eliminates the effects of the disease for those with a particular strand of cystic fibrosis, but which costs more than 300 thousand per year per patient.

The company which makes the drug - Vertex - has made a submission to PHARMAC's newly established rare diseases sub committee which is currently considering it along with 12 other applications.